Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020095249 - ANTI-LIV1 IMMUNE CELL CANCER THERAPY

Publication Number WO/2020/095249
Publication Date 14.05.2020
International Application No. PCT/IB2019/059586
International Filing Date 07.11.2019
IPC
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 14/725 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Applicants
  • CRISPR THERAPEUTICS AG [CH]/[CH]
Inventors
  • TERRETT, Jonathan Alexander
  • SAGERT, Jason
Priority Data
62/756,72307.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-LIV1 IMMUNE CELL CANCER THERAPY
(FR) THÉRAPIE CONTRE LE CANCER DES CELLULES IMMUNITAIRES ANTI-LIV1
Abstract
(EN)
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1+ malignancies.
(FR)
Dans certains modes de réalisation, l'invention concerne des procédés et des compositions (par exemple, des compositions cellulaires) pour le traitement du cancer, tels que des malignités LIV1+.
Latest bibliographic data on file with the International Bureau